Prophylactic or therapeutic medication for inner ear disorders

Abstract

Disclosed is a medication for the prevention or treatment of inner ear disorders that comprises a spirohydantoin derivative represented by general formula (I) (wherein, X represents a halogen atom or a hydrogen atom, and R1 and R2 together or independently represent a hydrogen atom or an optionally substituted C1-6 alkyl group.) or a pharmacologically acceptable salt thereof as an active component.

Description

technical field [0001] The present invention relates to a medicine for preventing or treating inner ear disorders, which contains a compound having an aldose reductase inhibitory activity as an active ingredient. Background technique [0002] The inner ear disorder refers to a disorder in which inner ear hard of hearing, inner ear tinnitus, and inner ear vertigo are frequently caused due to a disorder in the inner ear. Inner ear hearing loss is caused by age, disease, genetic factors, or noise. In 2009 it was estimated that about 14% (38 million people) of US adults had some degree of inner ear hard of hearing. Inner ear tinnitus is the phenomenon of hearing sound when there is no sound source in the outside world. In inner ear vertigo, severe rotational vertigo is confirmed, often accompanied by nausea, vomiting, and tinnitus. The current situation is that there is no effective treatment for inner ear hearing loss, inner ear tinnitus and inner ear vertigo. [0003] Rega...

AI Technical Summary

Problems solved by technology

However, there are no reports of its use for inner ear disorders

In addition, there is no report showing the use for inner ear disorders with other aldose reductase inhibitors

Images